Nominum-led Panel Discussion at BlackHat Focuses on the Agility and Coverage Depth of DNS in Discovering and Blocking New Malware
Nominum™, the DNS-based security and services innovation leader, announced today it is leading a panel discussion at BlackHat USA titled “DNS: An Agile Defense Against Diverse, Damaging Attacks.” The panel of speakers features security researcher Nick Feamster, Professor and Deputy Director of the Princeton University Center for Information Technology Policy (CITP), and Matthew Carothers, Principal Security Architect with a leading North American ISP, along with Nominum security experts Yuriy Yuzifovich, Head of Security Research and Data Science, and Pierre Ehsani, Senior Director of Product Management.
The discussion will shed light on the depth and breadth of cyberthreats that can be detected and analyzed using DNS data – all in a matter of minutes – when it is combined with machine learning and proprietary algorithms. While DNS performs an essential network service, connecting users with applications and services they seek, security related enhancements turn DNS into an agile defense that can protect consumers and businesses against a wide range of web threats.
The Nominum-led panel session takes place at 2:30pm PDT on Thursday, July 27, 2017 in Oceanside F, Level 2 at the Mandalay Bay Hotel in Las Vegas. More information can be found at https://www.blackhat.com/us-17/business-hall/schedule/#dns-an-agile-defense-against-diverse-damaging-attacks-8213.
“The vast majority of cyberattacks rely on DNS to be successful. By examining DNS traffic, it is possible to pinpoint the unique queries these threats use to carry out their exploits,” said Yuriy Yuzifovich, Head of Security Research and Data Science for Nominum. “In fact, DNS data often detects malware faster, and finds more malware than alternative approaches like intensive forensic analysis of hosts. For devices like POS terminals and IoT gadgets that have little to no built-in security and are difficult to scan for malware, a DNS-based approach is highly effective.”
Nominum Data Science uses anonymized service provider, commercial and public data sources, along with advanced predictive intelligence techniques to analyze over 100 billion queries daily. The team combines its unique visibility into worldwide real-time DNS data and a patent-pending, unsupervised machine learning algorithm based on a neural network, to pick up correlation signals between domain names. This technology helps discover obscure domains that cybercriminals use to hide behind multiple machine-generated domains, including Domain Generated Algorithms (DGAs).
Nominum™ is a pioneer and global leader in DNS-based security and services innovation. The Silicon Valley company provides an integrated suite of carrier-grade DNS-based solutions that enable fixed and mobile operators to protect and enhance their networks, strengthen security for business and residential subscribers and offer innovative value-added services that can be monetized. The result is improved service agility, higher ARPU, increased brand loyalty and a strong competitive advantage. More than 130 service providers in over 40 countries trust Nominum to deliver a safe, customizable internet and promote greater value to over half a billion users. Nominum DNS software resolves 1.7 trillion queries around the globe every day—roughly 100 times more transactions than the combined daily volume of tweets, likes, and searches taking place on major web properties. For more information visit nominum.com.
Follow us on Twitter: @nominum https://twitter.com/nominum
Follow us on LinkedIn: https://www.linkedin.com/company/nominum
See us on YouTube: https://www.youtube.com/nominum
Read our latest blogs: http://nominum.com/blog/ | http://nominum.com/tech-blog/
Nancy MacGregor, +1-415-309-5185
Om Business Wire
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Shell, bio-bean and Coffee-Drinkers Collaborate to Help Power London’s Buses20.11.2017 00:01 | Pressemelding
Shell and bio-bean announce that together they are helping to power some of London’s buses using a biofuel made partly from waste coffee grounds. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171119005060/en/ Shell and bio-bean announce that together they are helping to power some of London's buses using a biofuel made partly from waste coffee grounds (Photo: Business Wire) The B20 biofuel contains a 20% bio-component which contains part coffee oil. The biofuel is being added to the London bus fuel supply chain and will help to power some of the buses; without need for modification. Biofuel provides a cleaner, more sustainable energy solution for buses across London’s network by decreasing emissions1. “Our Coffee Logs have already become the fuel of choice for households looking for a
Samsung Bioepis Receives Regulatory Approval for Europe's First Trastuzumab Biosimilar, ONTRUZANT®19.11.2017 22:21 | Pressemelding
Samsung Bioepis Co., Ltd. today announced the European Commission’s (EC) marketing authorization of ONTRUZANT ® , a biosimilar referencing Herceptin ® (trastuzumab), for the treatment of early breast cancer, metastatic breast cancer and metastatic gastric cancer. ONTRUZANT ® is the first trastuzumab biosimilar to receive regulatory approval in Europe. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171119005066/en/ Christopher Hansung Ko, President & CEO of Samsung Bioepis. (Photo: Business Wire) The EC approval of ONTRUZANT ® applies to all 28 European Union (EU) member states and the European Economic Area (EEA) member states of Norway, Iceland and Liechtenstein. ONTRUZANT ® will be commercial
Cancer Patients, Survivors, Supporters and Caregivers Undertake UAE's First Relay for Life19.11.2017 16:31 | Pressemelding
Sharjah, the third largest of the United Arab Emirate’s seven emirates, was the host for the MENA region’s first ever ‘Global Relay for Life,’ (RFL) a 24-hour walkathon that is the biggest fundraising event for cancer in the world. Conducted in conjunction with the American Cancer Society, the event was organised by Friends of Cancer Patients (FoCP), a non-profit organisation that supports cancer patients and their families. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171119005048/en/ During MENA's first Global Relay For Life walkathon - Source: Friends of Cancer Patients Taking place November 17-18 at the American University Sharjah, the inaugural UAE RFL saw more than 2,000 relayers participating in the overnight event, with a large number of individuals and institutions involved including 52 sch
New Data Show Benefit of Tagrisso in Patients with EGFR-mutated Non-small Cell Lung Cancer and Central Nervous System Metastases18.11.2017 23:00 | Pressemelding
AstraZeneca today presented new data from a subgroup analysis of the Phase III FLAURA trial, which explored osimertinib as 1st-line therapy in patients with locally advanced or metastatic epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC). Results presented at the ESMO Asia 2017 Congress in Singapore showed that patients with central nervous system (CNS) metastases at baseline had a higher objective response rate with their brain metastasis and suggest a lower risk of CNS progression when treated with osimertinib, a third-generation, irreversible EGFR tyrosine kinase inhibitor (TKI), versus current standard-of-care EGFR-TKIs (erlotinib or gefitinib) [Abstract LBA5].1 The analysis included patients with ≥1 measurable and/or non-measurable CNS lesion present on baseline scan (as assessed by blinded independent central review), accounting for 23
New England Journal of Medicine Publishes Results of Phase III FLAURA Trial in the 1st-Line Treatment of EGFR-mutated Non-small Cell Lung Cancer18.11.2017 18:20 | Pressemelding
AstraZeneca today announced that the New England Journal of Medicine has published the positive results from the Phase III FLAURA trial which provide data for Tagrisso’s (osimertinib) use in the 1st-line treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC).1 The trial showed a statistically significant, clinically meaningful progression-free survival (PFS) advantage for osimertinib, a third-generation, irreversible EGFR tyrosine kinase inhibitor (TKI), compared with current 1st-line EGFR-TKIs, erlotinib or gefitinib.1 This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171118005044/en/ Dr. Suresh S. Ramalingam, Principal Investigator of the FLAURA trial, from the Winship Cancer Institute
Much-Anticipated CHTF 2017 Top 10 Products Are Unveiled18.11.2017 09:11 | Pressemelding
The 19th China Hi-Tech Fair (CHTF 2017), with the theme of “Innovation-Driven Development and Supply Quality Upgrade”, is taking place from November 16 to 21 at Shenzhen Convention and Exhibition Center. On the afternoon of November 10, the CHTF 2017 Top 10 Products were unveiled at the awards ceremony by Mr. Gao Zimin, Vice Mayor of Shenzhen City. A total of 322 entries competed for the honor Top 10 Products, and the voting lasted nearly 3 months. 60 candidate products in the fields of new energy, 3D print, flexible display, life sciences, unmanned vehicles and AI were shortlisted by the organizer, experts and media representatives and went for open voting online. The final Top 10 Products all represent the most advanced technologies in their respective sectors: the water-making device that can make water out of air, the smart sportswear that can monitor heartbeat and other
I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.Besøk vårt presserom